Immunotherapy is also applied, with good clinical outcomes, in HER2+ breast cancer and TNBC due to the high amount of tumor-infiltrating lymphocytes and high expression of programmed death ligand 1 (PD-L1), which is the main target of this treatment strategy [67]. This evidence concerns the gene ERBB2 and breast cancer.